Clinical trial · Observational
Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma.
Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma: An Observational Cohort Study.
NCT07449637CI-TRIAL-00104594not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to learn about the different treatment options for intermediate-stage hepatocellular carcinoma. The main question it aims to answer is: \- What are the survival outcomes among participants aged 18 or older who receive treatment for intermediate-stage hepatocellular carcinoma?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| BCLC Stage B Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients with intermediate-stage hepatocellular carcinoma (BCLC-B)
Primary outcomes (4)
- measure
- Overall Survival (OS)
- timeFrame
- From randomization to the end of treatment at 5 years.
- description
- Overall survival (OS) is defined as the time from randomization to death.
- measure
- Progression-Free Survival (PFS)
- timeFrame
- From randomization to the end of treatment at 5 years.
- description
- Progression-free survival (PFS) is defined as the time from randomization until first evidence of disease progression or death.
- measure
- Objective response (mRECIST)
- timeFrame
- From randomization to the end of treatment at 5 years.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged ≥18 years. * Both sexes. * Diagnosis of hepatocellular carcinoma based on accepted radiologic or histologic criteria. * Classified as intermediate stage (BCLC-B) at time of decision for first-line treatment. * Child-Pugh A or B. * ECOG performance status 0-1. Exclusion Criteria: * BCLC A, C, or D at diagnosis. * Prior curative therapy (resection, transplantation, curative ablation). * Missing essential data (imaging, liver function, treatment records). * Mixed HCC-cholangiocarcinoma.
References
Publications (0)
Data not yet available
No reference posted for this study.